The objectives of this meta-analysis were evaluating the efficacy of crizotinib, assessing ORR between Asians and Caucasians, comparing the efficacy according to line of treatment in patients with locally advanced or metastatic ALK-positive NSCLC. Here, ALK is linked to non-small cell lung carcinoma.